Condition: Post Menopausal Osteoporosis · Sponsor: Centre Hospitalier Universitaire de Saint Etienne
Post-menopausal osteoporosis and the resulting fractures are an important cause of disability and loss of independence. They also increase the risk of morbidity and mortality. Given potential side effects, hormone replacement therapy is no longer recommended for menopausal women with risk of becoming osteoporotic. The very significant decrease in the use of these treatments is suspected of contributing to a resurgence in the incidence of osteoporotic fractures, particularly in women before the age of 70. There is a need for prevention of osteoporosis.
This description comes directly from the study's public registry record.
Adamah AMOUZOUGAN, MD · (0)477120595 · amadah.amouzougan@chu-st-etienne.fr
Florence RANCON, CRA · (0)477829458 · florence.rancon@chu-st-etienne.fr
Always discuss trial participation with your own doctor first.
| Hôpital Gabriel Montpied | Clermont-Ferrand, France | Not Yet Recruiting |
| Clinique Universitaire de Rhumatologie | Grenoble, France | Not Yet Recruiting |
| CH Emile Roux | Le Puy-en-Velay, France | Not Yet Recruiting |
| Hôpital Edouard Herriot | Lyon, France | Not Yet Recruiting |
| APHP - Hôpital Cochin | Paris, France | Not Yet Recruiting |
| CH Roanne | Roanne, France | Not Yet Recruiting |
| CHU Saint-Etienne | Saint-Etienne, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05571514